Rumors are swirling that Johnson & Johnson (NYSE:JNJ), a major medtech company that’s indicated it’s hunting for deals, could acquire TransEnterix (NYSEMKT:TRXC), a tiny company working on robotic surgery systems led by Todd Pope, former global president of Cordis, which was once a J&J division. Although no one knows if J&J (or anyone else) will offer to buy TransEnterix, and rumors are usually a sure-fire way for investors to run into trouble, here are five charts that show why TransEnterix’ acquisition rumors may have merit.
